InsiderTrades

Form 4 for DMAC DiaMedica Therapeutics Inc.

Accepted 2022-12-08 00:00:00 ET · period of report 2022-12-06 · accession 0001235802-22-000134 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
M 2022-12-08 2022-12-06+ DMAC Giuffre Randall Michael Dir P - Purchase $1.40 +24.9K 180.6K +16% +$34.7K

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Voting Common Shares, no par value per share 2022-12-07 P A 22,574 $1.40 203,146 D — — (F2) The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.36 to $1.40, inclusive. The reporting person undertakes to provide to DiaMedica Therapeutics Inc., any security holder of DiaMedica Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4. (F1) Includes 4,146 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan, 29,829 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan, 107,811 voting common shares held by Michael Giuffre and his wife jointly and 61,360 voting common shares held by Michael Giuffre individually.
2 Common Voting Common Shares, no par value per share 2022-12-06 P A 2,300 $1.35 180,572 D — — (F1) Includes 4,146 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan, 29,829 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan, 107,811 voting common shares held by Michael Giuffre and his wife jointly and 61,360 voting common shares held by Michael Giuffre individually.